Literature DB >> 36262514

Anti-reflux versus conventional self-expanding metal stents in the palliation of esophageal cancer: A systematic review and meta-analysis.

João Guilherme Ribeiro Jordão Sasso1, Diogo Turiani Hourneaux de Moura1, Igor Mendonça Proença1, Epifânio Silvino do Monte Junior1, Igor Braga Ribeiro1, Sergio A Sánchez-Luna2, Spencer Cheng1, Alexandre Moraes Bestetti1, Angelo So Taa Kum1, Wanderley Marques Bernardo1, Eduardo Guimarães Hourneaux de Moura1.   

Abstract

Background and study aims  Self-expanding metal stents (SEMS) are an effective palliative endoscopic therapy to reduce dysphagia in esophageal cancer. Gastroesophageal reflux disease (GERD) is a relatively common complaint after non-valved conventional SEMS placement. Therefore, valved self-expanding metal stents (SEMS-V) were designed to reduce the rate of GERD symptoms. We aimed to perform a systematic review and meta-analysis comparing the two stents. Material and methods  This was a systematic review and meta-analysis including only randomized clinical trials (RCT) comparing the outcomes between SEMS-V and non-valved self-expanding metal stents (SEMS-NV) following the Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines. The risk of bias was assessed using the Cochrane Risk of Bias 2 tool. Data were analyzed with Review Manager Software. Quality of evidence was evaluated using Grading of Recommendations Assessment, Development, and Evaluation guidelines. Results  Ten randomized clinical trials including a total of 467 patients, 234 in the SEMS-V group and 233 in the SEMS-NV group, were included. There were no statistically significant differences regarding GERD qualitative analysis (RD -0.17; 95 % CI -0.67, 0.33; P  = 0.5) and quantitative analysis (SMD -0.22; 95 % CI -0.53, 0.08; P  = 0.15) technical success (RD -0.03; 95 % CI -0.07, 0.01; P  = 0.16), dysphagia improvement (RD -0.07; 95 % CI -0.19, 0.06; P  = 0.30), and adverse events (RD 0.07; 95 % CI -0.07, 0.20; P  = 0.32). Conclusions  Both SEMS-V and SEMS-NV are safe and effective in the palliation of esophageal cancer with similar rates of GERD, dysphagia relief, technical success, adverse events, stent migration, stent obstruction, bleeding, and improvement of the quality of life. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Entities:  

Year:  2022        PMID: 36262514      PMCID: PMC9576338          DOI: 10.1055/a-1894-0914

Source DB:  PubMed          Journal:  Endosc Int Open        ISSN: 2196-9736


  37 in total

1.  STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.

Authors:  Dan Turner; Amanda Ricciuto; Ayanna Lewis; Ferdinando D'Amico; Jasbir Dhaliwal; Anne M Griffiths; Dominik Bettenworth; William J Sandborn; Bruce E Sands; Walter Reinisch; Jürgen Schölmerich; Willem Bemelman; Silvio Danese; Jean Yves Mary; David Rubin; Jean-Frederic Colombel; Laurent Peyrin-Biroulet; Iris Dotan; Maria T Abreu; Axel Dignass
Journal:  Gastroenterology       Date:  2021-02-19       Impact factor: 22.682

2.  Management of malignant stricture of the esophagogastric junction with a newly designed self-expanding metal stent with an antireflux mechanism.

Authors:  C S Shim; I S Jung; Y K Cheon; C B Ryu; S J Hong; J O Kim; J Y Cho; J S Lee; M S Lee; B S Kim
Journal:  Endoscopy       Date:  2005-04       Impact factor: 10.093

3.  How much progress have we made?: a 20-year experience regarding esophageal stents for the palliation of malignant dysphagia.

Authors:  Shria Kumar; Firas Bahdi; Ikenna K Emelogu; Abraham C Yu; Martin Coronel; Philip S Ge; Emmanuel Coronel; Jaffer A Ajani; Brian Weston; Patrick Lynch; William A Ross; Jeffrey H Lee
Journal:  Dis Esophagus       Date:  2022-06-15       Impact factor: 3.429

4.  Superiority of anti-reflux stent compared with conventional stents in the palliative management of patients with cancer of the lower esophagus and esophago-gastric junction: results of a randomized clinical trial.

Authors:  C Power; P J Byrne; K Lim; N Ravi; J Moore; T Fitzgerald; P W N Keeling; J V Reynolds
Journal:  Dis Esophagus       Date:  2007       Impact factor: 3.429

5.  Evidence-based choice of esophageal stent for the palliative management of malignant dysphagia.

Authors:  Danny Yakoub; Ramy Fahmy; Thanos Athanasiou; Afshin Alijani; Christopher Rao; Ara Darzi; George B Hanna
Journal:  World J Surg       Date:  2008-09       Impact factor: 3.352

6.  Self-expandable metal stent placement for malignant esophageal strictures - changes in clinical outcomes over time.

Authors:  Agnes N Reijm; Paul Didden; Sara J C Schelling; Peter D Siersema; Marco J Bruno; Manon C W Spaander
Journal:  Endoscopy       Date:  2018-07-10       Impact factor: 10.093

7.  Quality of life measurement in patients with oesophageal cancer.

Authors:  J M Blazeby; M H Williams; S T Brookes; D Alderson; J R Farndon
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

8.  Age-specific incidence, treatment, and survival trends in esophageal cancer: a Dutch population-based cohort study.

Authors:  Ali Al-Kaabi; Nikolaj S Baranov; Rachel S van der Post; Erik J Schoon; Camiel Rosman; Hanneke W M van Laarhoven; Marcel Verheij; Rob H A Verhoeven; Peter D Siersema
Journal:  Acta Oncol       Date:  2022-02-03       Impact factor: 4.089

9.  Antireflux versus conventional self-expanding metallic Stents (SEMS) for distal esophageal cancer: results of a multicenter randomized trial.

Authors:  E Coron; G David; S Lecleire; J Jacques; A Le Sidaner; T Barrioz; D Coumaros; C Volteau; B Vedrenne; P Bichard; C Boustière; Y Touchefeu; J Brégeon; F Prat; M Le Rhun
Journal:  Endosc Int Open       Date:  2016-06

10.  Is young-onset esophageal adenocarcinoma increasing in Japan? An analysis of population-based cancer registries.

Authors:  Eiko Saito; Tomonori Yano; Megumi Hori; Daisuke Yoneoka; Tomohiro Matsuda; Yichi Chen; Kota Katanoda
Journal:  Cancer Med       Date:  2022-01-25       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.